Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Corning Incorporated (GLW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Corning Incorporated — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Corning Incorporated trades at $185.4 (market cap $159.55B). The key difference: Corning Incorporated is far larger — about 35.5× ACADIA Pharmaceuticals Inc.'s market cap, and Corning Incorporated pays a 0.6% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GLW | |
|---|---|---|
Market Cap | $4.49B | $159.55B |
Sector | Health | Technology |
52-Week High | $28.06 | $255.79 |
52-Week Low | $20.06 | $51.60 |
Enterprise Value | $3.69B | $167.71B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Corning Inc. (GLW) trades at $185.38, down 5.75% amid recent AI-related stock volatility, yet maintains strong fundamentals with Q1 2026 EPS beating estimates at $0.70. Revenue grew to $15.63B in 2025, with net income margin improving to 10.21%. Technical indicators show a bullish overall signal despite near-term bearish moving averages, with key support at $185. Recent news highlights AI-driven fiber demand as a growth catalyst, though competition and China exposure pose risks.
The outlook remains positive with a consensus price target of $206.60, implying 11.4% upside, supported by 54% analyst buy ratings. Risks include high valuation multiples (P/E 93.65) and dependency on AI infrastructure spending cycles. Institutional sentiment is bullish, but investors should monitor earnings consistency and macroeconomic pressures on tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
